Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eleclazine in Long QT Syndrome Type 3
NCT02300558Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of eleclazine in Long QT Syndrome Type 3 (LQT3), sponsored by Gilead Sciences. Started Dec 2014; status: terminated.
02
Drugs
eleclazine
03
Conditions
Long QT Syndrome Type 3 (LQT3)
Beyond the preview
Go deeper on NCT02300558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300558.